LivingGLP1
Study S002701

DRIVE Program: Diabetes Remote Intervention to improVe Use of Evidence-based Medications

ClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration
NCT06046560
Acronym
DRIVE
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE4
Masking
NONE
Status
COMPLETED
Enrollment
200
Start
2021-03-22
Primary completion
2023-07-25
Lead sponsor
Brigham and Women's Hospital
Conditions
Cardiovascular Diseases; Diabetes
Interventions
DRUG:SGLT2 inhibitor, GLP-1 RA; BEHAVIORAL:Education-First
Results posted
TRUE

Registered primary outcomes

  • Number of Patients With Prescriptions of SGLT2i or GLP1-RA at Any Time [Any time between 0-months (baseline) to 6-months following enrollment]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0003866Safety of a remote disease management program to improve sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists prescribing in type 2 diabetes with elevated cardiovascular or kidney risk.
Chang LS, American heart journal
2026Randomized trialPMID 41610902DOIcites ClinicalTrials.gov:NCT06046560; registry reference DERIVED:41610902
R0010709Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.
Blood AJ, Circulation
2024Randomized trialPMID 38583146DOIcites ClinicalTrials.gov:NCT06046560; registry reference RESULT:38583146
R0029244Methods, rationale, and design for a remote pharmacist and navigator-driven disease management program to improve guideline-directed medical therapy in patients with type 2 diabetes at elevated cardiovascular and/or kidney risk.
Blood AJ, Primary care diabetes
2024ProtocolPMID 38302335DOIregistry reference BACKGROUND:38302335